Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1595-1600

  Kluin Nelemans, H C ^a   van Marwijk Kooy, M ^b   Lugtenburg, P J ^c   van Putten, W L J ^c   Luten, M ^c   Oudejans, J ^d   van Imhoff, G W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Alemtuzumab; EBV; Immunochemotherapy; T cell lymphoma; T cell non Hodgkin's lymphoma

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; CLEMASTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; GANCICLOVIR; PARACETAMOL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VALACICLOVIR; VINCRISTINE;

ADULT; AGED; ALOPECIA; AMBULATORY MONITORING; ARTICLE; BEDTIME DOSAGE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; EYE DISEASE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HERPES SIMPLEX; HUMAN; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; LUNG DISEASE; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALE; METABOLIC DISORDER; MONOTHERAPY; MUCOSAL CONGESTION; MUCOSAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PAIN; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; RIGOR; SALVAGE THERAPY; SIDE EFFECT; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; UROGENITAL TRACT DISEASE; VIRUS REACTIVATION; VOMITING;

EID: 79959726585     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq635     Document Type: Article

References (40)

1. Armitage JO, Greer JP, Levine AM et al. Peripheral T-cell lymphoma. Cancer 1989; 63: 158-163.
2. Armitage JO, Weisenburger DD. Non-Hodgkins lymphoma Classif Proj. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Clin Oncol 1998; 16: 2780-2795.
3. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 124-4130.
4. Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004; 5: 289-303.
5. Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Blood 2010; 116: 3418-3425.
6. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721-1726.
7. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; 19 (Suppl): S27-S32.
8. Keating MJ, Cazin B, Coutre S et al. Campath-1H treatment of T-Cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-213.
9. Pawson R, Dyer MJS, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667-2672.
10. Ravandi F, Aribi A, O'Brien S et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009; 27: 5425-5430.
11. Lundin J, Hagberg H, Repp R et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272.
12. Agostinelli C, Piccaluga PP, Went P et al. Peripheral T-cell lymphoma not otherwise-specified: the stuff of genes, dreams and therapies. J Clin Pathol 2008; 61: 1160-1167.
13. Piccaluga PP, Agostinelli C, Righi S et al. Expression of CD52 in peripheral T-cell lymphoma. Haematol 2007; 92: 566-567.
14. Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185-191.
15. Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapyrefractory peripheral T-cell lymphomas. Blood 2004; 103: 2920-2924.
16. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
17. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
18. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
19. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
20. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51: 1372-1383.
21. Kluin-Nelemans HC, Coenen JL, Boers JE et al. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008; 112: 039-1041.
22. Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective ulticenter trial. Blood 2007; 110: 2316-2323.
23. Kim JG, Sohn SK, Chae YS et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother harmacol 2007; 60: 129-134.
24. Gutiérrez A, Caballero MD, Perez-Manga G et al. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant 2008; 42: 773-781.
25. Horwitz SM. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008; 2008: 289-296.
26. Kyriakou C, Canals C, Goldstone A et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 218-224.
27. Rodriguez J, Caballero MD, Gutierrez A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GELTAMO experience. Ann ncol 2003; 14: 1768-1775.
28. Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin ncol 2009; 27: 106-113.
29. D#Amore F, Jantunen E, Relander T. Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how? Curr Hematol Malig Rep 2009; 4: 236-244.
30. Chang ST, Lu CL, Chuang SS. CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 2007; 48: 117-121.
31. Rodig SJ, Abramson JS, Pinkus GS et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12: 7174-7179.
32. Jiang L, Yuan CM, Hubacheck J et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009; 145: 173-179.
33. Geissinger E, Bonzheim I, Roth S et al. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor ntibodies. Leuk Lymphoma 2009; 50: 1010-1016.
34. Elter T, Molnar I, Kuhlmann J et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008; 49: 2256-2262.
35. Andreone P, Gramenzi A, Lorenzini S et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163: 1997-2004.
36. Bakker NA, Van Imhoff GW. Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematol 2007; 92: 1447-1450.
37. Weisel KC, Weidmann E, Anagnostopoulos I et al. Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J ematol 2008; 88: 434-440.
38. O'Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657-2663.
39. Sohani AR, Ferry JA, Chang PS et al. Epstein-Barr virus-positive diffuse large B-Cell lymphoma during therapy with alemtuzumab for T-Cell prolymphocytic leukemia. J Clin ncol 2010; 28: e69-e72.
40. Zettl A, Lee SS, Rudiger T et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002; 117: 368-379.